Document is current
Any future updates will be listed below
-
Authors
Gordillo-Marañón, María https://orcid.org/0000-0003-2993-6577
Szmigiel, Agnieszka https://orcid.org/0009-0006-6049-9634
Yalmanová, Vladimíra https://orcid.org/0009-0002-4947-0479
Caplanusi, Irina https://orcid.org/0009-0006-0694-4469
Genov, Georgy https://orcid.org/0009-0000-5139-3981
Olsen, David Benee https://orcid.org/0009-0006-7117-8182
Straus, Sabine https://orcid.org/0009-0006-9266-3312
- License Information
-
More Information
Article History
Accepted: 20 March 2024
First Online: 12 April 2024
Declarations
:
: No funding was received to assist with the preparation of this article.
: María Gordillo-Marañón, Agnieszka Szmigiel, Vladimíra Yalmanová, Irina Caplanusi, Georgy Genov, David Benee Olsen and Sabine Straus have no conflicts of interest that are directly relevant to the content of this article. María Gordillo-Marañón, Agnieszka Szmigiel, Vladimíra Yalmanova, Irina Caplanusi and Georgy Genov are employees of the European Medicines Agency. Sabine Straus is the Chair of European Medicines Agency’s Pharmacovigilance Risk Assessment Committee and employee of the Medicines Evaluation Board, the Netherlands. David Benee Olsen is a member of the European Medicines Agency Pharmacovigilance Risk Assessment Committee and employee of the Norwegian Medical Products Agency, Norway.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MGo-M and AS have shared first authorship. All authors contributed towards the writing of the text and have read and approved the final manuscript.
